Trevena to Release First Quarter 2022 Financial Results on May 11, 2022

Rhea-AI Summary

Trevena, Inc. (Nasdaq: TRVN) plans to release its first-quarter financial results for 2022 on May 11, 2022, before the market opens. A conference call and webcast will be held at 8:00 a.m. ET featuring key company executives. Trevena is focused on developing innovative medicines for CNS disorders and currently has one approved product, OLINVYK, for managing acute pain. The company is also developing four investigational drug candidates targeting various conditions.

Positive

• The company has one approved product, OLINVYK, for acute pain management.
• Trevena's pipeline includes four investigational drug candidates targeting important medical conditions.

Negative

• None.

Company to host a Conference Call & Webcast at 8:00 a.m. ET

CHESTERBROOK, Pa., May 09, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it will release its financial results for the first quarter ended March 31, 2022, prior to the market open on Wednesday, May 11, 2022.

The Company will host a conference call and webcast with the investment community at 8:00 a.m. ET that same day, featuring remarks by Carrie Bourdow, President and Chief Executive Officer, Patricia Drake, SVP and Chief Commercial Officer, Mark Demitrack, M.D., SVP and Chief Medical Officer, and Barry Shin, SVP and Chief Financial Officer.

Title:	Trevena First Quarter 2022 Financial Results Conference Call & Webcast
Date:	Wednesday, May 11, 2022
Time:	8:00 a.m. ET
Conference Call Details:	Toll-Free: 1-844-826-3033 International: 1-412-317-5185 Conference ID: 10166614
The conference call will be webcast live from the Company’s website and will be available via the following link:
Webcast:	https://viavid.webcasts.com/starthere.jsp?ei=1545824&tp_key=fa08098dd7

The webcast should be accessed 15 minutes prior to the conference call start time. A replay of the webcast will be available following the conclusion of the live broadcast and will be accessible on the Company’s website.

About Trevena
Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative medicines for patients with CNS disorders. The Company has one approved product in the United States, OLINVYK^® (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Company’s novel pipeline is based on Nobel Prize winning research and includes four differentiated investigational drug candidates: TRV045 for diabetic neuropathic pain and epilepsy, TRV027 for acute respiratory distress syndrome and abnormal blood clotting in COVID-19 patients, TRV250 for the acute treatment of migraine and TRV734 for maintenance treatment of opioid use disorder.

For more information, please visit www.Trevena.com

For more information, please contact:

Investor Contact:
Dan Ferry - Managing Director
LifeSci Advisors, LLC
daniel@lifesciadvisors.com
(617) 430-7576

Company Contact:
Bob Yoder
SVP and Chief Business Officer
Trevena, Inc.
(610) 354-8840

FAQ

When will Trevena release its first-quarter 2022 financial results?

Trevena will release its first-quarter financial results on May 11, 2022, prior to the market open.

What time is Trevena's conference call scheduled?

The conference call is scheduled for 8:00 a.m. ET on May 11, 2022.

How can I access Trevena's conference call?

You can access Trevena's conference call via a toll-free number at 1-844-826-3033 or internationally at 1-412-317-5185 using the conference ID 10166614.

What is Trevena's main focus as a biopharmaceutical company?

Trevena focuses on the development and commercialization of innovative medicines for patients with central nervous system disorders.